Unknown

Dataset Information

0

Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.


ABSTRACT: The FLT3 internal tandem duplication (Flt3-ITD) confers a worse prognosis for patients with acute myeloid leukemia (AML); however, the mechanisms involved are unknown. As AML is treated with cytarabine (Ara-C) and an anthracycline, we sought to determine the effects of the Flt3-ITD on response to these agents.A genetically defined mouse model of AML was used to examine the effects of the Flt3-ITD on response to cytarabine and doxorubicin in vitro and in vivo.In vitro, the Flt3-ITD conferred resistance to doxorubicin and doxorubicin plus Ara-C, but sensitivity to Ara-C alone. This resistance was reversible by the Flt3-ITD inhibitor sorafenib. The Flt3-ITD did not affect DNA damage levels after treatment, but was associated with increased levels of p53. The p53 response was critical to the observed changes as the Flt3-ITD had no effect on chemotherapy response in the setting of p53 null AML. In vivo, the Flt3-ITD accelerated engraftment that was partially reversible by Ara-C but not doxorubicin. Additionally, Ara-C provided a significant reduction in disease burden and a survival advantage that was not increased by the addition of doxorubicin. Doxorubicin alone led to only minimal disease reduction and no survival benefit.These data demonstrate that the Flt3-ITD confers sensitivity to Ara-C, but resistance to doxorubicin in a manner that depends on p53. Thus, patients with Flt3-ITD positive AML may not benefit from treatment with an anthracycline.

SUBMITTER: Pardee TS 

PROVIDER: S-EPMC3062750 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.

Pardee Timothy S TS   Zuber Johannes J   Lowe Scott W SW  

Experimental hematology 20110201 4


<h4>Objective</h4>The FLT3 internal tandem duplication (Flt3-ITD) confers a worse prognosis for patients with acute myeloid leukemia (AML); however, the mechanisms involved are unknown. As AML is treated with cytarabine (Ara-C) and an anthracycline, we sought to determine the effects of the Flt3-ITD on response to these agents.<h4>Materials and methods</h4>A genetically defined mouse model of AML was used to examine the effects of the Flt3-ITD on response to cytarabine and doxorubicin in vitro a  ...[more]

Similar Datasets

| S-EPMC4840097 | biostudies-literature
| S-EPMC5395123 | biostudies-literature
| S-EPMC3501718 | biostudies-literature
| S-EPMC8979819 | biostudies-literature
| S-EPMC5045383 | biostudies-literature
| S-EPMC8184771 | biostudies-literature
2014-12-31 | GSE56241 | GEO
| S-EPMC4987127 | biostudies-literature
| S-EPMC9809327 | biostudies-literature
| S-EPMC9070948 | biostudies-literature